Innovent Biologics, Takeda, IBI363, TAK-928, cancer immunotherapy, PD-1 inhibitor, IL-2 fusion protein, NSCLC, gastric cancer, gastroesophageal junction adenocarcinoma

Suzhou, China, and San Francisco, California, USA, October 26, 2026 Innovent Biologics has announced new clinical data for IBI363...